MINERALYS THERAPEUTICS ($MLYS) posted quarterly earnings results for Q4 2025 on Thursday, March 12th. The company reported earnings of -$0.40 per share, beating estimates of -$0.54 by $0.14. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $MLYS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MINERALYS THERAPEUTICS Insider Trading Activity
MINERALYS THERAPEUTICS insiders have traded $MLYS stock on the open market 49 times in the past 6 months. Of those trades, 0 have been purchases and 49 have been sales.
Here’s a breakdown of recent trading of $MLYS stock by insiders over the last 6 months:
- BRIAN TAYLOR SLINGSBY sold 1,000,000 shares for an estimated $43,350,000
- DAVID MALCOM RODMAN (Chief Medical Officer) has made 0 purchases and 19 sales selling 337,661 shares for an estimated $11,735,253.
- JON CONGLETON (Chief Executive Officer) has made 0 purchases and 10 sales selling 231,336 shares for an estimated $10,262,465.
- ADAM SCOTT LEVY (CFO and Secretary) has made 0 purchases and 12 sales selling 141,040 shares for an estimated $6,161,422.
- ALEXANDER M GOLD has made 0 purchases and 5 sales selling 34,675 shares for an estimated $1,576,094.
- DAPHNE KARYDAS has made 0 purchases and 2 sales selling 15,000 shares for an estimated $689,797.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
MINERALYS THERAPEUTICS Hedge Fund Activity
We have seen 130 institutional investors add shares of MINERALYS THERAPEUTICS stock to their portfolio, and 106 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 2,986,254 shares (+144.2%) to their portfolio in Q4 2025, for an estimated $108,371,157
- STATE STREET CORP added 1,881,976 shares (+144.4%) to their portfolio in Q4 2025, for an estimated $68,296,909
- CITADEL ADVISORS LLC removed 1,667,308 shares (-80.7%) from their portfolio in Q4 2025, for an estimated $60,506,607
- SAMLYN CAPITAL, LLC added 1,304,932 shares (+inf%) to their portfolio in Q4 2025, for an estimated $47,355,982
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,303,737 shares (+6097.1%) to their portfolio in Q4 2025, for an estimated $47,312,615
- CAPITAL INTERNATIONAL INVESTORS removed 1,230,106 shares (-51.4%) from their portfolio in Q4 2025, for an estimated $44,640,546
- JANUS HENDERSON GROUP PLC added 1,193,417 shares (+6012.8%) to their portfolio in Q4 2025, for an estimated $43,309,102
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
MINERALYS THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $MLYS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 12/19/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/12/2025
To track analyst ratings and price targets for MINERALYS THERAPEUTICS, check out Quiver Quantitative's $MLYS forecast page.
MINERALYS THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $MLYS recently. We have seen 3 analysts offer price targets for $MLYS in the last 6 months, with a median target of $55.0.
Here are some recent targets:
- Annabel Samimy from Stifel set a target price of $52.0 on 12/19/2025
- Matthew Caufield from HC Wainwright & Co. set a target price of $56.0 on 11/12/2025
- Mohit Bansal from Wells Fargo set a target price of $55.0 on 11/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
